BAIYUNSHAN PH: Malic acid sunitinib has received approval for the listing application of chemical raw materials
BAIYUNSHAN PH announced that its subsidiary Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Baiyunshan Chemical Pharmaceutical Factory recently received the approval notice for the marketing application of Succinic Acid Sunitinib from the National Medical Products Administration. Succinic Acid Sunitinib is a new oral multi-targeted anti-tumor drug primarily used for the treatment of gastrointestinal stromal tumors, advanced renal cell carcinoma, and advanced pancreatic neuroendocrine tumors
According to the announcement from Zhitong Finance APP, Baiyunshan (600332.SH) recently stated that its subsidiary, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Baiyunshan Chemical Pharmaceutical Factory (referred to as "Baiyunshan Chemical Pharmaceutical Factory"), has received the "Approval Notice for the Listing Application of Succinic Acid Sunitinib" issued by the National Medical Products Administration (referred to as "NMPA").
It is reported that Succinic Acid Sunitinib is a new oral multi-target anti-tumor drug that was launched in the United States in February 2006, under the brand name Sutent. Its main indications include the treatment of gastrointestinal stromal tumors (GIST) that have failed or cannot tolerate Imatinib Mesylate, advanced renal cell carcinoma (RCC) that cannot be surgically removed, and advanced pancreatic and other endocrine tumors